VolitionRx Reports 112% H1 Revenue Growth, Advances Toward $5M Veterinary Milestone
112% H1 Revenue Growth, Advance Toward $5 Million Veterinary Milestone, Newly Announced Collaboration and Active Licensing Discussions with More Than a Dozen Global Diagnostic LeadersHENDERSON, Nev., Aug. 26, 2026
VolitionRx doubled its money made in the first half of the year and is working with big companies to sell more pet health tests. When a small company grows fast and partners with leaders in its field, it shows people believe in what they're doing.
Last session drawn · prints held ~15 minutes · licensed exchange data
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only — not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.